vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Douglas Elliman Inc. (DOUG). Click either name above to swap in a different company.
Douglas Elliman Inc. is the larger business by last-quarter revenue ($245.4M vs $180.9M, roughly 1.4× AVANOS MEDICAL, INC.). Douglas Elliman Inc. runs the higher net margin — 27.9% vs -0.7%, a 28.7% gap on every dollar of revenue. On growth, Douglas Elliman Inc. posted the faster year-over-year revenue change (0.9% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-14.7M). Over the past eight quarters, Douglas Elliman Inc.'s revenue compounded faster (10.7% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Douglas Elliman Inc. is a leading U.S.-based residential real estate brokerage firm. It offers luxury property sales, rentals, property management, and advisory solutions, serving high-net-worth clients across key metro markets including New York, California, Florida, and Texas.
AVNS vs DOUG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $245.4M |
| Net Profit | $-1.3M | $68.6M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 27.3% |
| Net Margin | -0.7% | 27.9% |
| Revenue YoY | 0.7% | 0.9% |
| Net Profit YoY | 99.7% | 1243.4% |
| EPS (diluted) | $-0.02 | $0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $245.4M | ||
| Q3 25 | $177.8M | $262.8M | ||
| Q2 25 | $175.0M | $271.4M | ||
| Q1 25 | $167.5M | $253.4M | ||
| Q4 24 | $179.6M | $243.3M | ||
| Q3 24 | $170.4M | $266.3M | ||
| Q2 24 | $171.7M | $285.8M | ||
| Q1 24 | $166.1M | $200.2M |
| Q4 25 | $-1.3M | $68.6M | ||
| Q3 25 | $-1.4M | $-24.7M | ||
| Q2 25 | $-76.8M | $-22.7M | ||
| Q1 25 | $6.6M | $-6.0M | ||
| Q4 24 | $-397.3M | $-6.0M | ||
| Q3 24 | $4.3M | $-27.2M | ||
| Q2 24 | $1.8M | $-1.7M | ||
| Q1 24 | $-900.0K | $-41.5M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 27.3% | ||
| Q3 25 | 0.1% | -4.1% | ||
| Q2 25 | -42.6% | -2.0% | ||
| Q1 25 | 6.1% | -2.1% | ||
| Q4 24 | -233.0% | -6.7% | ||
| Q3 24 | 7.0% | -2.8% | ||
| Q2 24 | 3.7% | -1.3% | ||
| Q1 24 | 2.4% | -20.7% |
| Q4 25 | -0.7% | 27.9% | ||
| Q3 25 | -0.8% | -9.4% | ||
| Q2 25 | -43.9% | -8.4% | ||
| Q1 25 | 3.9% | -2.4% | ||
| Q4 24 | -221.2% | -2.5% | ||
| Q3 24 | 2.5% | -10.2% | ||
| Q2 24 | 1.0% | -0.6% | ||
| Q1 24 | -0.5% | -20.7% |
| Q4 25 | $-0.02 | $0.80 | ||
| Q3 25 | $-0.03 | $-0.29 | ||
| Q2 25 | $-1.66 | $-0.27 | ||
| Q1 25 | $0.14 | $-0.07 | ||
| Q4 24 | $-8.64 | $-0.06 | ||
| Q3 24 | $0.09 | $-0.33 | ||
| Q2 24 | $0.04 | $-0.02 | ||
| Q1 24 | $-0.02 | $-0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $115.5M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $183.9M |
| Total Assets | $1.1B | $444.4M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $115.5M | ||
| Q3 25 | $70.5M | $143.0M | ||
| Q2 25 | $90.3M | $136.3M | ||
| Q1 25 | $97.0M | $136.8M | ||
| Q4 24 | $107.7M | $145.5M | ||
| Q3 24 | $89.0M | $151.4M | ||
| Q2 24 | $92.2M | $92.9M | ||
| Q1 24 | $75.8M | $91.5M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $183.9M | ||
| Q3 25 | $778.0M | $115.1M | ||
| Q2 25 | $776.3M | $137.6M | ||
| Q1 25 | $839.4M | $158.2M | ||
| Q4 24 | $828.5M | $162.2M | ||
| Q3 24 | $1.2B | $173.6M | ||
| Q2 24 | $1.2B | $196.9M | ||
| Q1 24 | $1.2B | $195.1M |
| Q4 25 | $1.1B | $444.4M | ||
| Q3 25 | $1.1B | $480.6M | ||
| Q2 25 | $1.0B | $489.0M | ||
| Q1 25 | $1.1B | $493.9M | ||
| Q4 24 | $1.2B | $493.9M | ||
| Q3 24 | $1.7B | $502.7M | ||
| Q2 24 | $1.7B | $463.9M | ||
| Q1 24 | $1.7B | $461.1M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-14.4M |
| Free Cash FlowOCF − Capex | $21.3M | $-14.7M |
| FCF MarginFCF / Revenue | 11.8% | -6.0% |
| Capex IntensityCapex / Revenue | 3.8% | 0.1% |
| Cash ConversionOCF / Net Profit | — | -0.21× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-17.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $-14.4M | ||
| Q3 25 | $14.0M | $5.5M | ||
| Q2 25 | $6.8M | $642.0K | ||
| Q1 25 | $25.7M | $-5.6M | ||
| Q4 24 | $57.9M | $-9.0M | ||
| Q3 24 | $23.0M | $9.0M | ||
| Q2 24 | $27.8M | $1.3M | ||
| Q1 24 | $-8.0M | $-27.3M |
| Q4 25 | $21.3M | $-14.7M | ||
| Q3 25 | $7.0M | $4.7M | ||
| Q2 25 | $-4.2M | $-575.0K | ||
| Q1 25 | $19.0M | $-6.7M | ||
| Q4 24 | $53.1M | $-10.2M | ||
| Q3 24 | $20.0M | $7.7M | ||
| Q2 24 | $21.9M | $432.0K | ||
| Q1 24 | $-12.1M | $-29.4M |
| Q4 25 | 11.8% | -6.0% | ||
| Q3 25 | 3.9% | 1.8% | ||
| Q2 25 | -2.4% | -0.2% | ||
| Q1 25 | 11.3% | -2.6% | ||
| Q4 24 | 29.6% | -4.2% | ||
| Q3 24 | 11.7% | 2.9% | ||
| Q2 24 | 12.8% | 0.2% | ||
| Q1 24 | -7.3% | -14.7% |
| Q4 25 | 3.8% | 0.1% | ||
| Q3 25 | 3.9% | 0.3% | ||
| Q2 25 | 6.3% | 0.4% | ||
| Q1 25 | 4.0% | 0.4% | ||
| Q4 24 | 2.7% | 0.5% | ||
| Q3 24 | 1.8% | 0.5% | ||
| Q2 24 | 3.4% | 0.3% | ||
| Q1 24 | 2.5% | 1.0% |
| Q4 25 | — | -0.21× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
DOUG
| Commissions And Other Brokerage Income | $240.3M | 98% |
| Property Management Income | $2.8M | 1% |
| Property Management | $2.2M | 1% |
